EDMONTON, July 31 /CNW/ - (ISA:TSX): Isotechnika Inc. today announced
that its partner, Lux Biosciences, presented preclinical data demonstrating
the safety and pharmacokinetics of LX214 as a potential once-daily topical
treatment for chronic inflammatory diseases of the eye. LX214 is a clear,
micellar topical formulation of voclosporin, Isotechnika's next-generation
calcineurin inhibitor, which is being developed by Lux Biosciences as a
potential treatment for such conditions as dry eye syndrome, blepharitis, and
atopic keratoconjunctivitis.
